Project Grant R01CA288736

Award Date 6/1/24
Completion Date 5/31/29
Dollars Obligated $2.3M
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Torrance, CA 90502, USA
Similar Awards
This $398,728 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of a novel homologous recombination (HR) inhibitor, CP-8, to sensitize triple-negative breast cancer (TNBC) cells to DNA-damaging agents. The project aims to examine the synergy of CP-8 with various DNA-damaging therapies, including PARP inhibitors and ionizing radiation, in TNBC cell lines, patient-derived xenograft models, and in vivo...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research into the mechanisms underlying breast cancer development in BRCA1 mutation carriers. The total award of $527,159 will fund a 5-year project at Brigham & Women's Hospital Inc., a prominent academic medical center in Boston, Massachusetts. The key research objectives are to: 1) Determine if BRCA1-deficient luminal mammary epithelial cells acquire a fetal mammary stem...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding of $676,584 to the University of Texas MD Anderson Cancer Center to investigate the genomic and transcriptomic evolution of metastatic precursor cells and the tumor microenvironment in triple-negative breast cancer (TNBC) metastasis. The key objectives are to: 1) study the genomic and phenotypic evolution of metastatic precursor cells during metastatic dissemination; 2)...
This $3.3 million project grant from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) supports research to identify prediagnostic exposures, germline genetics, and immune and mutational profiles associated with triple negative breast cancer (TNBC). Joan & Sanford I Weill Medical College of Cornell University is the primary awardee and will perform whole exome sequencing of tumor and germline DNA from 400 TNBC patients across four prospective cohort...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) for $342,569 aims to elucidate the distinct regulatory mechanisms of the protein APE1 in activating the ATR checkpoint signaling pathway in cancer cells. The key products and services to be delivered under this 5-year grant include: Determining how APE1 forms liquid-liquid phase separation in the nucleoli of cancer cells (but not normal cells) to promote the ATR-CHK1 checkpoint...
This federal Project Grant award of $545,983 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research at Northwestern University to identify molecular regulators of circulating tumor cell (CTC) interactions with the host immune system, with a focus on triple-negative breast cancer (TNBC). The key objectives are to: Determine the clinical relevance of the PlexinB2 (PB2) protein network in TNBC, as PB2 drives CTC cluster formation and interactions with...
This Project Grant award, titled "TARGETING METABOLIC VULNERABILITIES OF TRIPLE NEGATIVE BREAST CANCER STEM CELLS," is funded by the National Cancer Institute (CFDA Program 93.395 - Cancer Treatment Research). The $474,547 grant will support research by the Regents of the University of Michigan to investigate novel therapeutic approaches for targeting cancer stem-like cells in triple negative breast cancer (TNBC), an aggressive cancer subtype with few treatment options. The research...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Research Manpower program (CFDA 93.398) to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct research on ribonucleotide reductase (RNR) as a target for inhibiting breast cancer aggressiveness and metastasis. The $340,072 grant, awarded on September 20, 2024, will fund studies to evaluate a novel, non-nucleoside RNR inhibitor called TMU27A. The research aims to determine if...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop novel therapies for advanced metastatic triple-negative breast cancer (TNBC). The $622,329 award to Virginia Commonwealth University aims to modulate the growth, progression, and metastasis of TNBC by inhibiting the MDA-9 protein. Key objectives include: 1) formulating an MDA-9 inhibitor called PDZ1I for clinical use and characterizing its effects on the immune...
This Project Grant award of $442,343, funded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research to improve outcomes for patients with triple negative breast cancer (TNBC). The primary objectives are to: Test the hypothesis that copper depletion using tetrathiomolybdate (TM) can disrupt key aspects of TNBC metastasis, including cancer cell bioenergetics, the pre-metastatic niche, and stromal remodeling. This will be evaluated through a...

DECIPHERING FUNCTIONS OF THE ATR-METTL3-BRCA1 AXIS IN GENOME INSTABILITY AND TUMORIGENESIS - PROJECT SUMMARY /ABSTRACT A DEFECT IN DNA DAMAGE REPAIR TRIGGERS GENOME INSTABILITY AS A HALLMARK OF CANCER THAT IS EXPLOITED BY TREATMENTS SUCH AS IONIZING RADIATION, PLATINUM CHEMOTHERAPY AND POLY (ADP-RIBOSE) POLYMERASE INHIBITORS (PARPI). PATHOGENIC GERMLINE AND SOMATIC VARIANTS IN THE DNA REPAIR GENE BRCA1 ARE FREQUENTLY DETECTED IN TRIPLE NEGATIVE BREAST CANCER (TNBC) AND BRCA1-MUTATED TNBC CAN BE TARGETED WITH PARPI TO ACHIEVE A CLINICAL RESPONSE. ELUCIDATING THE MECHANISM(S) BY WHICH BRCA1 AND ITS ASSOCIATED PARTNERS RESOLVE DNA LESIONS WILL PROVIDE NEW INSIGHTS INTO HOW GENOME INSTABILITY PROMOTES CELLULAR TRANSFORMATION AND IDENTIFY NEW THERAPEUTIC TARGETS. IN THIS PROPOSAL, WE WILL INVESTIGATE FUNCTIONS OF THE ATR-METTL3-BRCA1 AXIS IN R-LOOP ASSOCIATED DNA DAMAGE TO SUSTAIN STABLE GENOME. PERSISTENT AND UNSCHEDULED R-LOOPS CREATE STRUCTURAL BARRIERS WHEN THEY COLLIDE WITH COLLAPSED REPLICATION FORKS OR DOUBLE STRAND BREAKS (DSB) TO ELICIT GENOME INSTABILITY. OUR PRELIMINARY DATA FOUND THAT METTL3, A PROTEIN PROMOTING RNA M6A MODIFICATION WHEN R-LOOPS FORM DURING TRANSCRIPTION, IS RECRUITED TO REPAIR DNA LESIONS AT ACTIVE TRANSCRIPTION SITES. METTL3 IS PHOSPHORYLATED BY ATR, A KEY KINASE IN R-LOOP ASSOCIATED DNA DAMAGE SIGNALING, AND THIS PHOSPHORYLATION PROMOTES ASSOCIATION WITH BRCA1. WE FOUND THAT BRCA1 IS BOTH NECESSARY AND SUFFICIENT FOR METTL3 RECRUITMENT TO DNA DAMAGE SITES. WE IDENTIFIED SEVERAL BREAST CANCER ASSOCIATED METTL3 MUTATIONS AND FOUND THAT TWO CATALYTICALLY INACTIVE MUTATIONS IMPEDE HR REPAIR BY ABOLISHING THE ASSOCIATION WITH BRCA1. OUR PROTEOMIC ANALYSIS HAS IDENTIFIED A DNA/RNA HELICASE THAT RESOLVES R-LOOPS AS THE EFFECTOR OF THE ATR-METTL3-BRCA1 AXIS. FURTHERMORE, INHIBITION OF METTL3 CATALYTIC ACTIVITY WITH A SMALL MOLECULE INDUCES A DEFECT IN HOMOLOGOUS RECOMBINATION AND ENHANCES PARPI SENSITIVITY IN TNBC CELL LINES. WE HYPOTHESIZE THAT THE ATR-METTL3-BRCA1 AXIS IS CRITICAL FOR THE R-LOOP- ASSOCIATED DNA DAMAGE REPAIR AND BREAST CANCER DEVELOPMENT AND OFFERS A NEW THERAPEUTIC TARGET FOR TNBC. WE WILL TEST THIS HYPOTHESIS IN THE FOLLOWING SPECIFIC AIMS. IN AIM 1, WE WILL ELUCIDATE MECHANISMS BY WHICH METTL3 SERINE 43 PHOSPHORYLATION PROMOTES DNA/RNA HELICASE RECRUITMENT TO RESOLVE R-LOOP ASSOCIATED DNA DAMAGE. IN AIM 2, WE WILL DETERMINE THE ROLES OF THE ATR-METTL3-BRCA1 AXIS IN BREAST CANCER DEVELOPMENT WITH MOUSE MODELS. IN AIM 3, WE WILL TARGET THE ATR-METTL3-BRCA1 AXIS WITH A METTL3 INHIBITOR IN TNBC. OUR STUDIES WILL UNRAVEL A NOVEL FUNCTION FOR METTL3 IN DNA REPAIR AND IDENTIFY METTL3 AS A PROMISING THERAPEUTIC TARGET IN TNBC.

Posted 5/30/24, 12:00 AM